Kelvin Capital backed ProFactor Pharma Ltd (PFP), has completed an important development milestone in its research that will transform the treatment of ‘Haemophilia A’.

Based outside Edinburgh at the Easter Bush Campus, the company has received £1.1m (the second tranche of funding from its £2m funding round announced in September 2019) to advance its R&D programme, which is moving closer to toxicology studies for its low cost recombinant human factor VIII (rhFVIII) for the treatment of ‘Haemophilia A’.